HUTCHMED (China) (HMDCF) Net Shares Issued and Repurchased (2015 - 2024)
HUTCHMED (China)'s (HMDCF) quarterly Net Shares Issued and Repurchased came in at -$36.1 million in Q4 2024, down 297.57% year-over-year from $18.3 million in Q1 2024, and little changed quarter-over-quarter from -$36.1 million in Q2 2024.
Analysis
HUTCHMED (China) (HMDCF) Net Shares Issued and Repurchased (2015 - 2024) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Net Shares Issued and Repurchased for 10 consecutive years, with -$36.1 million the latest figure, recorded in Q4 2024.
- On a quarterly basis, Net Shares Issued and Repurchased fell 297.57% year-over-year to -$36.1 million in Q4 2024; TTM through Dec 2024 was -$36.1 million, a 297.57% decrease from a year earlier, with the FY2024 full-year figure at -$36.1 million, down 297.57% from the prior year.
- Net Shares Issued and Repurchased was -$36.1 million for Q4 2024 at HUTCHMED (China), roughly flat from -$36.1 million in the prior quarter.
- Over five years, Net Shares Issued and Repurchased peaked at -$9.1 million in Q2 2023 and troughed at -$48.1 million in Q2 2022.
- A 5-year average of -$26.6 million and a median of -$26.8 million in 2021 frame the typical range for Net Shares Issued and Repurchased.
- Across the five-year window, Net Shares Issued and Repurchased tumbled 3629.48% in 2020 and soared 81.14% in 2023, its largest moves.
- Over 5 years, Net Shares Issued and Repurchased stood at -$12.9 million in 2020, then sank by 111.63% to -$27.3 million in 2021, then slumped by 76.07% to -$48.1 million in 2022, then soared by 81.14% to -$9.1 million in 2023, then slumped by 297.57% to -$36.1 million in 2024.
- The last three Net Shares Issued and Repurchased figures came in at -$36.1 million (Q4 2024), -$36.1 million (Q2 2024), and -$9.1 million (Q4 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -36.06 Mn |
| Jun 30, 2024 | -36.06 Mn |
| Dec 31, 2023 | -9.07 Mn |
| Jun 30, 2023 | -9.07 Mn |
| Dec 31, 2022 | -48.08 Mn |
| Jun 30, 2022 | -48.08 Mn |
| Dec 31, 2021 | -27.31 Mn |
| Jun 30, 2021 | -26.76 Mn |
| Mar 31, 2021 | -26.76 Mn |
| Dec 31, 2020 | -12.90 Mn |
| Jun 30, 2020 | -12.90 Mn |
| Dec 31, 2019 | -346,000.00 |
| Sep 30, 2019 | -346,000.00 |
| Jun 30, 2019 | -346,000.00 |
| Mar 31, 2019 | -346,000.00 |
| Dec 31, 2018 | 5.45 Mn |
| Sep 30, 2018 | -5.45 Mn |
| Jun 30, 2018 | -5.45 Mn |
| Mar 31, 2018 | -5.45 Mn |
| Dec 31, 2017 | 1.37 Mn |